Evidence map›Paper›PMID 30070770›Full record

Trial reportClinical pharmacology in drug development2019

Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.

Claire Ambery, Graeme Young, Teresa Fuller, Alex Georgiou, David Ramsay, Adeep Puri, Peter Daley-Yates

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The future of inhalation therapy in chronic obstructive pulmonary disease.Current research in pharmacology and drug discovery · 2022
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claire AmberyClinical Pharmacology Modelling and Simulation (CPMS), GSK, Stockley Park West, Uxbridge, Middlesex, UK.
Graeme YoungBioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Teresa FullerGSK, Medicines Research Centre, Stevenage, Hertfordshire, UK.
Alex GeorgiouBioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
David RamsayQuanticate Ltd, Edinburgh, UK.
Adeep PuriHammersmith Medicines Research Ltd, London, UK.
Peter Daley-YatesClinical Development, GSK, Research and Development, Uxbridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aim was to investigate the pharmacokinetics of single high doses and repeated therapeutic doses of fluticasone furoate (FF) and batefenterol (BAT; a bifunctional muscarinic antagonist and β

Indexed as

AdultAndrostadienesArea Under CurveCarbamatesCross-Over StudiesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationFemaleHealthy VolunteersHumansMaleMiddle AgedQuinolonesYoung AdultAndrostadienesbatefenterolCarbamatesDrug Combinationsfluticasone furoateQuinolonesbatefenterolbifunctional moleculebronchodilatorfluticasone furoatetriple therapy

Identifiers

PMID30070770
PMCPMC6585707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.